InnoCare Pharma (SEHK:9969) Stock Could Be 45% Undervalued After EHA 2026 Data

Why InnoCare Pharma Stock Is In Focus After EHA 2026

InnoCare Pharma (SEHK:9969) has drawn fresh attention after presenting data from more than 40 clinical studies of its BTK inhibitor orelabrutinib at the European Hematology Association 2026 Congress.

The company highlighted outcomes across several hematological cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, and primary central nervous system lymphoma, using both monotherapy and combination regimens.

See our latest analysis for InnoCare Pharma.

Against this clinical backdrop, InnoCare Pharma’s share price closed at HK$10.84 after a 1 day share price return of 4.73%. However, the 30 day share price return is down 11.44% and the 1 year total shareholder return is down 16.23%, suggesting recent momentum remains weak, despite a 3 year total shareholder return that is up 68.06%.

If this kind of clinical news has your attention, it could be a moment to see what other healthcare related opportunities are setting up via the 131 healthcare AI stocks. You might find candidates that fit a similar risk and growth profile.

With InnoCare Pharma’s shares down over the past year but trading at a sizeable discount to analyst targets and some valuation estimates, the key question is simple: is this clinical progress underappreciated or already fully priced in?

Most Popular Narrative: 45% Undervalued

On the most followed narrative, InnoCare Pharma’s fair value of HK$19.62 sits well above the last close at HK$10.84. This puts a spotlight on what assumptions sit underneath that gap.

The analysts have a consensus price target of HK$19.62 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$22.32, and the most bearish reporting a price target of just HK$17.0.

Read the complete narrative.

Want to understand why a stock with forecast earnings pressure still screens as undervalued here? The narrative leans heavily on revenue growth, margin resets and a rich future earnings multiple that assumes investors keep paying up for this pipeline story.

Result: Fair Value of HK$19.62 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, InnoCare Pharma’s heavy R&D spend and dependence on orelabrutinib and a handful of key assets mean that any clinical or competitive setback could quickly challenge this undervaluation story.

Find out about the key risks to this InnoCare Pharma narrative.

Next Steps

If this mix of clinical promise and valuation debate around InnoCare Pharma feels finely balanced, consider acting promptly: study the data in detail and weigh both the potential upside and the risks by reviewing the 4 key rewards and 2 important warning signs

Looking for more investment ideas beyond InnoCare Pharma?

If you want a broader view than InnoCare Pharma alone, use the Simply Wall St Screener to quickly spot stocks that match your risk tolerance and return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com